Tuesday, November 8, 2016

BRIEF-Seattle Genetics and Takeda complete enrollment of phase 3 echelon-2 clinical trial evaluating adcetris (brentuximab vedotin) in frontline mature t-cell Lymphoma

* Seattle Genetics Inc - data from echelon-2 phase 3 trial

expected in 2017 to 2018 timeframe

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)